A 46-year-old Asian women was treated with a next-generation bioresorbable biostimulatory polycaprolactone (PCL)-based dermal filler to restore facial volume loss.
A polycaprolactone (PCL)-based dermal filler has been introduced to the esthetic market in 2010, representing a new class of biostimulatory dermal fillers with microspheres that are smooth and sphericalshaped for optimal biocompatibility. [1] [2] [3] The PCL-based dermal filler is composed of 30% synthetic PCL microspheres suspended in a 70%
aqueous carboxymethylcellulose (CMC) gel carrier, and its safety and efficacy has already been shown in several studies. [4] [5] [6] Furthermore, it not only acts as a filler with immediate volumizing effects, but also stimulates the growth of new collagen (neocollagenesis) replacing the volume loss. 7, 8 In this case study, the PCL-based dermal filler was used to treat the descending soft tissue and contour defects of a 46-year-old Asian women by total facial volume restoration in multiple tissue layers. The injection techniques and concepts were derived from the recommendations of use for this product 9 and modified from the author's previous experience of using the injectable poly-L-lactic acid (PLLA). 10 
| MATERIALS AND METHODS
A 46-year-old women was treated 2 years before the current treatment by the insertion of polydioxanone threads. The result from the polydioxanone threads was unsatisfying and did not correct the folds and the descending soft tissue in her face as desired. She therefore expressed her preference for a biostimulatory product with an immediate volumizing effect that lasts longer than 1 year. Considering the needs of the patient and the volumizing characteristics of the PCLbased dermal filler, this became the product of choice for her treatment. Ten syringes (1 mL each) of the PCL-based dermal filler were used (Ellans e â syringe was premixed with 0.2 mL, 2% lidocaine before use.
product was placed into the supraperiosteal (SP) plane by vertical punctures with a 27G 1" needle ( Figure 1 ). The amount injected was determined by the surface areas to be treated using 0.2 mL/cm 2 .
For superficial fat (SF) and deep fat (DF) placement, a retrograde fanning technique was performed using 25G, 40 mm cannulas (Figure 1) . The amount injected was also determined by the surface areas to be treated, with each linear thread containing 0.1 mL/cm.
The treatment was carried out in the following sequence: The PCL microspheres of the product are homogeneously suspended in the CMC gel carrier. The gel carries a high viscosity and elasticity and provides an immediate filling effect to the treated area, while the PCL microspheres stimulate the growth of collagen as the gel is gradually degraded. By placing the product deeply on the bone, it is possible to increase the surface area of bony platform that holds the soft tissue envelop covering above it, and by placing the product in a fanning and crosshatching fashion, the product in threads restores volume in the supporting fat compartments as scaffolds, and further, to correct the descending superficial fat compartments above them, to achieve a rejuvenated proportion of the face. As opposed to the PCL-based dermal filler, the injectable PLLA is reconstituted in sterile water before injection. As the water is quickly absorbed by the body, the total injected volume decreases, which could lead to a relatively high rate of nodule formation due to particles moving close to each other. In conclusion, total facial rejuvenation to correct descending soft tissue with the PCL-based dermal filler was achieved through volume restoration in multiple tissue layers.
While the above results show the effectivity of the PCL-based dermal filler, it would also be interesting to show its effectivity compared to other dermal fillers in a future comparative study. Also, based on previous studies, 9,12 the above volume restoration results with the PCL-based dermal filler at 12 weeks follow-up are expected to be long-lasting; however, this has to be investigated in a follow-up study.
ACKNOWLEDGMENTS
The consent and the permission of the provided figures have been fully granted by the patient.
CONF LICT OF I NTEREST
The author has no conflict of interest or financial ties to disclose.
O R C I D
Shang-Li Lin http://orcid.org/0000-0003-4249-6852
